Company News 29 Apr 2022 Quarterly Report | Period To 31 March 2022 Orthocell has today published its Quarterly Report for the period ended 31 March 2022. Standout achievements for this Quarter include:… Orthocell
Media, Video 22 Mar 2022 VIDEO | Proactive Investors – March 2022 Orthocell CEO and Managing Director Paul Anderson spoke with Andrew Scott from Proactive Investors about passing a key milestone in… Orthocell
Company News 21 Mar 2022 TGA Approval for Remplir™ Orthocell’s Remplir™ device has gained Australian regulatory (Therapeutics Goods Administration) approval. Orthocell
Company News 28 Feb 2022 Striate+™ Market Update Orthocell’s Striate+™ dental membrane, which facilitates high quality and efficient bone and tissue repair, is gaining commercial momentum. Orthocell
Company News 11 Feb 2022 Meet Orthocell’s Quality Director, Monique Cannon On International Day of Women In Science, we’re proud to shine a spotlight on Orthocell’s Quality Director, Monique Cannon. Orthocell
Company News 31 Jan 2022 Quarterly Report – Period To December 2021 Orthocell (ASX $OCC) has today published its Quarterly Report for the period ended 31 December 2021. Orthocell
Media 13 Dec 2021 RADIO INTERVIEW | Bulls N’ Bears Report Orthocell (ASX $OCC) MD, Paul Anderson, was interviewed by Matt Birney on the Bulls N’ Bears Report about our latest… Orthocell
Media 09 Dec 2021 The West Australian | Orthocell’s tendon injury treatment a game-changer, clinical trial finds Orthocell (ASX $OCC) has been featured in The West Australian in a story titled, “Orthocell’s tendon injury treatment a game-changer, clinical trial… Orthocell
Company News 08 Dec 2021 Positive clinical results for OrthoATIâ„¢ Orthocell (ASX $OCC)Â has today released positive clinical data for its OrthoATIâ„¢ tendon program, which shows that OrthoATIâ„¢ is statistically more… Orthocell
Company News 15 Nov 2021 Ortho-ATI® Update Orthocell (ASX $OCC) has today released an update on its Ortho-ATIâ„¢ rotator cuff tendon study – the database is now… Orthocell
